Cadence Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cadence Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,710	Closed	-$498K	–	699
2016 Q3	$498K	Buy	+5,710	New	+$540K	0.04%	478
2015 Q4	–	Sell	-16,260	Closed	-$1.69M	–	665
2015 Q3	$1.69M	Sell	16,260 -1,260	-7%	-$162K	0.12%	201
2015 Q2	$2.16M	Hold	17,520	–	–	0.12%	217
2015 Q1	$2.07M	Sell	17,520 -25,620	-59%	-$3.07M	0.13%	215
2014 Q4	$5.13M	Sell	43,140 -3,190	-7%	-$359K	0.3%	91
2014 Q3	$5.2M	Buy	+46,330	New	+$4.41M	0.27%	109
2013 Q4	–	Sell	-58,850	Closed	-$4.46M	–	656
2013 Q3	$4.46M	Buy	+58,850	New	+$4.68M	0.15%	269

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cadence Capital Management's VRTX Position: Q4 2016 in Review

Cadence Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 5,710 shares — an estimated $498K sold.

Cadence Capital Management first reported a position in VRTX in Q3 2013 and held it in 7 quarters. The position peaked at $5.2M in Q3 2014. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

Cadence Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Cadence Capital Management sold 5,710 Vertex Pharmaceuticals shares in Q4 2016, an estimated $498K.
Cadence Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Cadence Capital Management's Vertex Pharmaceuticals position peaked at $5.2M in Q3 2014.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Cadence Capital Management's 13F filing for Q4 2016, filed 1 Feb 2017.